“DT56a prevents postmenopausal osteoporosis.”
DT56a (Femarelle) stimulates bone formation in female rats.
OVX rats developed noticeable signs of osteoporosis, namely, significant decrease in
trabecular bone volume and in trabecular and cortical thickness. DT56a, like oestrogen,
restored the bone structure measurements of all tested parameters in the OVX rats to the
values obtained in the intact rats. In skeletal tissues, CK activity was elevated in both
treatment groups. However, in the uterus DT56a did not activate oestrogen receptors while
oestrogen did elevate CK activity.